Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints

Affiliations

Tracy Rupp et al. JAMA Intern Med. 2017.

. 2017 Feb 1;177(2):276-277.

doi: 10.1001/jamainternmed.2016.7761.

No abstract available

Comment in

Improving the Accelerated Pathway to Cancer Drug Approvals.
Bauer SR, Redberg RF. Bauer SR, et al. JAMA Intern Med. 2017 Feb 1;177(2):278. doi: 10.1001/jamainternmed.2016.7777. JAMA Intern Med. 2017. PMID: 27898987 No abstract available.
Setting the Record Straight on FDA Approvals in Oncology.
Blumenthal G, Kim G, Pazdur R. Blumenthal G, et al. JAMA Intern Med. 2017 Aug 1;177(8):1222. doi: 10.1001/jamainternmed.2017.2241. JAMA Intern Med. 2017. PMID: 28783827 No abstract available.
Setting the Record Straight on FDA Approvals in Oncology-Reply.
Zuckerman D. Zuckerman D. JAMA Intern Med. 2017 Aug 1;177(8):1222-1223. doi: 10.1001/jamainternmed.2017.2251. JAMA Intern Med. 2017. PMID: 28783833 No abstract available.
Setting the Record Straight on FDA Approvals in Oncology-Reply.
Bauer SR, Redberg RF. Bauer SR, et al. JAMA Intern Med. 2017 Aug 1;177(8):1223. doi: 10.1001/jamainternmed.2017.2254. JAMA Intern Med. 2017. PMID: 28783834 No abstract available.